Skip to main content
. 2022 Feb 12;101(4):781–788. doi: 10.1007/s00277-022-04781-3

Fig. 2.

Fig. 2

Overall survival. a Overall survival after a median follow-up of 9.6 years among 59 patients treated. b Overall survival of patients aged 50–64 years (blue curve) as compared to patients ≥ 65 years (red curve) (P = 0.002). c Overall survival of patients with disease progression within 24 months of 90Y-IT treatment (POD24) (red curve) as compared to patients without disease progression within 24 months (blue curve) (P = 0.004) in 47 evaluable patients